Selecting The Right eQMS To Maximize Quality Maturity

By Varun Venkatachalam and Jim Morris, IQS Consulting

The transition to electronic ‌quality ‌management ‌systems (eQMS) has been ongoing for a few decades with several main providers and a host of smaller providers. Large companies gravitate to the larger well-established systems while smaller development-stage or midsize companies will choose from a wide selection of providers.¹ Often, eQMS selection is driven by comfort with a current supplier short circuiting a needs assessment that considers the product portfolio, systems interface, adoption of AI, and user interface. Systems built primarily as documentation repositories are stretched to manage workflows such as complaints and deviations. And systems with user-friendly workflows have poor search capability. For eQMS setups to remain useful, they must be best-in-class in search, document management, event management, and intra-company system interface and incorporate AI capabilities. As regulators increasingly emphasize consistency, reliability, and proactive improvement, eQMS platforms must evolve beyond passive systems of record to active enablers of quality execution.

This is the first of several articles on eQMS. This first article of the series explores the following:

• The current eQMS landscape in pharma and biotech
• Why eQMS selection decisions matter more than ever
• What a future-ready eQMS must enable to strengthen a pharmaceutical quality system (PQS) and support continuous improvement

The eQMS Landscape In Pharma And Biotech

eQMS platforms were originally introduced to digitize documentation and provide traceability for regulated processes. Over time, they expanded to support deviations, CAPA, change control, training, audits, complaints, and risk management.

Today, most pharma and biotech organizations operate one or more of the following models:

• Legacy or on-premises enterprise eQMS – These include old school embedded platforms o bespoke in-house platforms.
• Cloud-based SaaS eQMS – These offer faster deployment and reduced infrastructure burden.
• Hybrid environments – Multiple systems are simultaneously in use, due to acquisitions, site differences, or for operational reasons.

The industry has largely shifted toward cloud-based deployments, driven by scalability, accelerated deployment, faster validation cycles, and reduced IT overhead. However, while the technology has modernized, the operating mindset has often not.² Many systems still replicate paper processes electronically rather than enabling better decisions, learning, and improvement.

Why Selecting The Right eQMS Is Critical

It is tempting to view eQMS selection as an IT or procurement exercise. In reality, it is a strategic quality decision with long-term operational consequences.

Across the sector, selection decisions are commonly influenced by:

• historical use within the organization,
• familiarity of quality or procurement leadership,
• perceived “industry standard” platforms, and
• incumbent vendor relationships.

Objective, requirement-driven evaluations are often secondary.

As a result, organizations often experience:

• slow enterprise adoption,
• user frustration (what we had before was better),
• heavy customization to force-fit workflows,
• slow deviation and CAPA closure, and
• limited data insight despite large volumes of quality data.

In short, organizations remain compliant, but their systems are inefficient and potentially ineffective.

From our perspective at IQS Consulting, this is a critical distinction. Compliance demonstrates that controls exist; effectiveness demonstrates that the system actually works under the pressure of real-world operational demands.¹ We recommend that companies carry out a methodical evaluation comparing vendors against agreed requirements and cost criteria.  The selected eQMS vendor should satisfy a prioritized requirements matrix, budget and meet company growth objectives.

eQMS And The Human Factor

Regulators have consistently shown that recurring deficiencies are rarely due to missing procedures.⁴ They are more often linked to how procedures are written, interpreted, and executed by people.

At the same time, the workforce is changing. Newer generations entering pharma and biotech are:

• digitally native,
• accustomed to intuitive, mobile-first tools, and
• uncomfortable with paper records and fragmented systems.

When an eQMS is difficult to use, people adapt. Workarounds emerge as offline notes, spreadsheets, emails, delayed entries. These behaviors quietly erode data integrity and weaken the PQS.

Usability is therefore not cosmetic. It directly affects:

• personnel actions and behaviors,
• escalation and decision timeliness, and
• completeness and accuracy of records.

An eQMS that people want to use becomes an extension of the PQS. One that people tolerate becomes a burden and a potential compliance risk. We recommend configurable solutions to adopt workflows that work for your company. Users should find the system interface pleasurable. For instance, an eQMS deployed on a Salesforce platform is likely to be easily adopted as users will already be familiar or quickly gain familiarity with the system.

eQMS As An Enabler Of Quality Maturity

Regulatory thinking has shifted from static compliance toward quality management maturity. Initiatives such as the FDA’s Quality Management Maturity⁵ (QMM) program explicitly recognize that mature organizations demonstrate consistency, reliability, and proactive improvement, not just adherence to procedures.

A future-ready eQMS³ must:

•  enable configuration changes based on evolving needs of the company and permit efficient linking between deviations, CAPA, complaints, change control, and risk management,
• allow extraction of performance signals (trends, closure rates) to help users improve operational performance, and
• provide management with metrics and useful dashboards concerning record status and record quality.

An eQMS is essentially a lens into the health and maturity of a company’s quality system. The eQMS dashboard should give management a snapshot of QMS health – not only how many records are in the system and how many remain open, but also the quality of those records.    

Platform Archetypes Observed In Practice

Across client engagements, IQS commonly encounters three broad eQMS archetypes:

Content-Centric Enterprise Platforms

Several platforms excel at standardization, document control, and global deployment. When configured to specific requirements, they support strong inspection readiness and consistency.

Their limitation arises when execution insight is not intentionally embedded in the design. Without thoughtful architecture, they risk becoming excellent systems of record rather than systems of learning and continuous improvement.

Workflow-Driven Quality Suites

Several platforms get praise for solid handling of workflows in areas like deviations, changes, and management reviews. They offer adequate flexibility and are configurable to match company workflows. However, configurability without constraint often leads to bloated workflows. For example, a deviation process that should require three approval steps may, after successive customizations, require seven approval steps, each adding time without adding value.

Cloud-Native, Data-First Platforms

Newer systems are built for the cloud; they are pieced together in modules, primed for data insights. These are easier to tweak and link up, and they exhibit strong reporting and data analytical capability.

As with any platform, their effectiveness depends not on features but on how clearly users are leveraging leading indicators and proactive measures of performance.

Across all archetypes, the differentiator is not the software, it is whether the system is deliberately aligned with how decisions are made, risks are escalated, and learning is sustained.

Aligning Technology With Quality Intent

An eQMS should not be viewed as a technology program, nor as a substitute for leadership, governance, or culture.

Too often, eQMS implementations focus on feature enablement or module deployment. IQS takes a different view: the value of an eQMS lies in the signals it reveals about behavior, decision-making, and system effectiveness over time.⁶

Accordingly, IQS approaches eQMS selection and use through three fundamental questions.

1. What are leadership priorities and commitment to quality?

This includes stated quality strategy, leadership intent, and QMS maturity objectives. Despite many organizations articulating exceptional commitments to patient safety, proactive risk management, and continuous improvement, the critical question is whether these values are meaningfully reflected in how the eQMS is structured. Specifically: what data is captured, what is prioritized, and what is measured versus what is merely documented? 

2. How are quality decisions actually made?

This examines how critical areas such as deviations, CAPA, change, and risk-based decisions are actually handled in the organization. How robust are the eQMS records? Do the records support risk-based decisions made by the quality unit? How consistently are root causes investigated, changes evaluated, and effectiveness verified? Every eQMS record should stand alone and tell the story with utmost clarity and confidence.

3. Will the system help anticipate risks and drive future quality objectives?

Beyond individual records, the eQMS should generate evidence such as recurrence patterns, effectiveness of corrective actions, record quality, and indicators of organizational learning. These signals are essential for understanding whether the PQS is continuously improving and meeting the needs of users across the company. An eQMS dashboard that functions as a maturity index of the PQS would be ideal.

In essence, these questions differentiate companies seeking highly mature quality systems from those companies which are simply capturing data and not managing data proactively.   

Conclusion

Electronic ‌quality ‌management ‌systems quit acting like neutral setups some time ago; they influence actions, nudge choices one way or another, and reflect how a company makes decisions and manages risk. Pharma and biotech companies are dealing with stricter oversight from regulators, a changing workforce, and increasing pressure on supply chains. Therefore, the function of the eQMS needs to change as well, moving away from simple storage depots for compliance to tools that maximize QMS maturity. eQMS vendor selection is the first step and one of the most consequential decisions a company will make in strengthening its quality systems.

Upcoming articles in this series on eQMS will explore implementation and optimization.

References

1. Industry eQMS adoption and cloud-migration surveys (ISPE, consulting benchmarks)
2. ISPE, Quality Culture and Digital Transformation publications
3. ISPE, GAMP 5 (2nd Edition): A Risk-Based Approach to Compliant GxP Systems
4. U.S. FDA, Drug Shortages Task Force Report, 2019 and MHRA & FDA inspection metrics (2018–2023)
5. FDA CDER, Quality Management Maturity (QMM) Program communications
6. PDA, Quality Culture and Maturity Models

About The Authors:

Varun Kolla Venkatachalam is a pharmaceutical quality and digital transformation consultant with over 15 years of experience, including consulting at PwC, EY, and NSF International. He champions digital solutions for quality management system improvement and specializes in eQMS platform selection, configuration, and implementation. Venkatachalam holds a Global Executive MBA in healthcare & life sciences from the Rotman School of Management, University of Toronto, and an MSc from the University of Warwick.

Jim Morris leads IQS Consulting, a Boston-based consultancy focused on quality management systems improvement, supply chain assurance, and combination product development. His experience spans 35 years in quality and manufacturing with several large and small pharmaceutical companies, including 15 years consulting in the sector.